Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation

Vijaya R Bhatt, Fausto R. Loberiza, Kim Schmit-Pokorny, Stephanie J. Lee

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the United States, insurance status has been implicated as a barrier to obtaining timely treatment. In this retrospective cohort study of 521 patients who underwent first hematopoietic cell transplantation (HCT), we investigated the association between timeliness of HCT and overall survival. Timeliness was operationally defined in the following 3 ways: (1) payer approval, from request for approval to actual payer approval; (2) transplantation speed, from payer approval to time of actual HCT; and (3) total time, from request for approval to HCT. Patients with private insurance had longer time to payer approval (P < .0001) than those with public payers but shorter time from approval to actual HCT (P < .0001) and total time to HCT (P < .0001). Multivariate Cox regression showed no significant differences in risk of death between slow and fast times in the 3 indices of timeliness in the models that used all patients (n = 509), autologous HCT in lymphoma (n = 278), and autologous HCT in multiple myeloma (n = 121). Additional studies to evaluate the effect of insurance timeliness on all patients for whom HCT is recommended, not just those who undergo HCT, should be conducted.

Original languageEnglish (US)
Pages (from-to)1117-1124
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume22
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Cell Transplantation
Insurance
Survival
Insurance Coverage
Multiple Myeloma
Lymphoma
Cohort Studies
Retrospective Studies
Transplantation

Keywords

  • Hematopoietic cell transplantation
  • Insurance approval
  • Private insurance
  • Public payer
  • Survival
  • Timeliness

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation. / Bhatt, Vijaya R; Loberiza, Fausto R.; Schmit-Pokorny, Kim; Lee, Stephanie J.

In: Biology of Blood and Marrow Transplantation, Vol. 22, No. 6, 01.06.2016, p. 1117-1124.

Research output: Contribution to journalArticle

@article{981fdf7cde9a4a33876295d42fe3c49d,
title = "Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation",
abstract = "In the United States, insurance status has been implicated as a barrier to obtaining timely treatment. In this retrospective cohort study of 521 patients who underwent first hematopoietic cell transplantation (HCT), we investigated the association between timeliness of HCT and overall survival. Timeliness was operationally defined in the following 3 ways: (1) payer approval, from request for approval to actual payer approval; (2) transplantation speed, from payer approval to time of actual HCT; and (3) total time, from request for approval to HCT. Patients with private insurance had longer time to payer approval (P < .0001) than those with public payers but shorter time from approval to actual HCT (P < .0001) and total time to HCT (P < .0001). Multivariate Cox regression showed no significant differences in risk of death between slow and fast times in the 3 indices of timeliness in the models that used all patients (n = 509), autologous HCT in lymphoma (n = 278), and autologous HCT in multiple myeloma (n = 121). Additional studies to evaluate the effect of insurance timeliness on all patients for whom HCT is recommended, not just those who undergo HCT, should be conducted.",
keywords = "Hematopoietic cell transplantation, Insurance approval, Private insurance, Public payer, Survival, Timeliness",
author = "Bhatt, {Vijaya R} and Loberiza, {Fausto R.} and Kim Schmit-Pokorny and Lee, {Stephanie J.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1016/j.bbmt.2016.03.008",
language = "English (US)",
volume = "22",
pages = "1117--1124",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation

AU - Bhatt, Vijaya R

AU - Loberiza, Fausto R.

AU - Schmit-Pokorny, Kim

AU - Lee, Stephanie J.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - In the United States, insurance status has been implicated as a barrier to obtaining timely treatment. In this retrospective cohort study of 521 patients who underwent first hematopoietic cell transplantation (HCT), we investigated the association between timeliness of HCT and overall survival. Timeliness was operationally defined in the following 3 ways: (1) payer approval, from request for approval to actual payer approval; (2) transplantation speed, from payer approval to time of actual HCT; and (3) total time, from request for approval to HCT. Patients with private insurance had longer time to payer approval (P < .0001) than those with public payers but shorter time from approval to actual HCT (P < .0001) and total time to HCT (P < .0001). Multivariate Cox regression showed no significant differences in risk of death between slow and fast times in the 3 indices of timeliness in the models that used all patients (n = 509), autologous HCT in lymphoma (n = 278), and autologous HCT in multiple myeloma (n = 121). Additional studies to evaluate the effect of insurance timeliness on all patients for whom HCT is recommended, not just those who undergo HCT, should be conducted.

AB - In the United States, insurance status has been implicated as a barrier to obtaining timely treatment. In this retrospective cohort study of 521 patients who underwent first hematopoietic cell transplantation (HCT), we investigated the association between timeliness of HCT and overall survival. Timeliness was operationally defined in the following 3 ways: (1) payer approval, from request for approval to actual payer approval; (2) transplantation speed, from payer approval to time of actual HCT; and (3) total time, from request for approval to HCT. Patients with private insurance had longer time to payer approval (P < .0001) than those with public payers but shorter time from approval to actual HCT (P < .0001) and total time to HCT (P < .0001). Multivariate Cox regression showed no significant differences in risk of death between slow and fast times in the 3 indices of timeliness in the models that used all patients (n = 509), autologous HCT in lymphoma (n = 278), and autologous HCT in multiple myeloma (n = 121). Additional studies to evaluate the effect of insurance timeliness on all patients for whom HCT is recommended, not just those who undergo HCT, should be conducted.

KW - Hematopoietic cell transplantation

KW - Insurance approval

KW - Private insurance

KW - Public payer

KW - Survival

KW - Timeliness

UR - http://www.scopus.com/inward/record.url?scp=84963596888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963596888&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2016.03.008

DO - 10.1016/j.bbmt.2016.03.008

M3 - Article

C2 - 26988742

AN - SCOPUS:84963596888

VL - 22

SP - 1117

EP - 1124

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -